O	0	3	The
O	4	10	effect
O	11	13	of
B-intervention	14	23	metformin
O	24	26	on
B-condition	27	36	apoptosis
O	37	39	in
O	40	41	a
O	42	48	breast
O	49	55	cancer
O	56	67	presurgical
O	68	73	trial
O	73	74	.

O	75	84	Metformin
O	85	88	has
O	89	93	been
O	94	104	associated
O	105	109	with
O	110	120	antitumour
O	121	129	activity
O	130	132	in
O	133	139	breast
O	140	146	cancer
O	147	148	(
O	148	150	BC
O	150	151	)
O	152	155	but
O	156	159	its
O	160	169	mechanism
O	170	177	remains
O	178	185	unclear
O	185	186	.

O	187	189	We
O	190	200	determined
O	201	208	whether
O	209	218	metformin
O	219	226	induced
O	227	228	a
O	229	239	modulation
O	240	242	of
O	243	252	apoptosis
O	253	255	by
O	256	264	terminal
O	265	281	deoxynucleotidyl
O	282	293	transferase
O	294	298	dUTP
O	299	303	nick
O	304	307	end
O	308	317	labelling
O	318	319	(
O	319	324	TUNEL
O	324	325	)
O	326	333	overall
O	334	337	and
O	338	340	by
O	341	348	insulin
O	349	359	resistance
O	360	366	status
O	367	369	in
O	370	371	a
O	372	383	presurgical
O	384	389	trial
O	389	390	.

O	391	400	Apoptosis
O	401	404	was
O	405	413	analysed
O	414	416	in
O	417	421	core
O	422	430	biopsies
O	431	434	and
O	435	437	in
O	438	446	surgical
O	447	454	samples
O	455	459	from
B-total-participants	460	463	100
B-eligibility	464	467	non
I-eligibility	467	468	-
I-eligibility	468	476	diabetic
I-eligibility	477	479	BC
I-eligibility	480	488	patients
O	489	502	participating
O	503	505	in
O	506	507	a
O	508	518	randomised
O	519	524	trial
O	525	527	of
O	528	537	metformin
O	538	540	vs
O	541	548	placebo
O	549	554	given
O	555	558	for
O	559	560	4
O	561	566	weeks
O	567	573	before
O	574	581	surgery
O	581	582	.

B-total-participants	583	589	Eighty
I-total-participants	589	590	-
I-total-participants	590	595	seven
O	596	604	subjects
O	605	606	(
B-intervention-participants	606	608	45
O	609	611	on
O	612	621	metformin
O	622	625	and
B-control-participants	626	628	42
O	629	631	on
B-control	632	639	placebo
O	639	640	)
O	641	645	were
O	646	656	assessable
O	657	660	for
O	661	666	TUNEL
O	667	678	measurement
O	679	681	at
O	682	686	both
O	687	691	time
O	692	698	points
O	698	699	.

B-outcome	700	705	TUNEL
I-outcome	706	712	levels
O	713	715	at
O	716	723	surgery
O	724	728	were
O	729	735	higher
O	736	740	than
O	741	745	that
O	746	748	at
O	749	757	baseline
O	758	762	core
O	763	769	biopsy
O	770	771	(
O	771	772	P
O	772	773	<
O	773	774	0
O	774	775	.
O	775	779	0001
O	779	780	)
O	780	781	,
O	782	790	although
O	791	793	no
O	794	804	difference
O	805	812	between
O	813	817	arms
O	818	821	was
O	822	827	noted
O	828	829	(
O	829	838	metformin
O	839	842	arm
O	842	843	:
O	844	850	median
O	851	861	difference
O	862	869	surgery
O	869	870	-
O	870	876	biopsy
O	877	883	levels
O	884	885	+
O	885	886	4
O	886	887	%
O	887	888	,
O	889	902	interquartile
O	903	908	range
O	909	910	(
O	910	913	IQR
O	913	914	)
O	914	915	:
O	916	917	2
O	917	918	-
O	918	920	12
O	920	921	;
O	922	929	placebo
O	930	933	arm
O	933	934	:
O	935	936	+
O	936	937	2
O	937	938	%
O	938	939	,
O	940	943	IQR
O	943	944	:
O	945	946	0
O	946	947	-
O	947	948	8
O	948	949	,
O	950	951	P
O	951	952	=
O	952	953	0
O	953	954	.
O	954	955	2
O	955	956	)
O	956	957	.

B-outcome	958	962	Ki67
I-outcome	963	972	labelling
I-outcome	973	978	index
I-outcome	979	982	and
I-outcome	983	988	TUNEL
I-outcome	989	995	levels
O	996	1000	were
O	1001	1009	directly
O	1010	1020	correlated
O	1021	1025	both
O	1026	1028	at
O	1029	1037	baseline
O	1038	1041	and
O	1042	1049	surgery
O	1050	1051	(
O	1051	1059	Spearman
O	1059	1060	'
O	1060	1061	s
O	1062	1063	r
O	1063	1064	=
O	1064	1065	0
O	1065	1066	.
O	1066	1068	51
O	1068	1069	,
O	1070	1071	P
O	1071	1072	<
O	1072	1073	0
O	1073	1074	.
O	1074	1078	0001
O	1078	1079	)
O	1079	1080	.

O	1081	1083	In
O	1084	1087	the
O	1088	1090	59
O	1091	1096	women
B-outcome	1097	1104	without
I-outcome	1105	1112	insulin
I-outcome	1113	1123	resistance
O	1124	1125	(
O	1125	1129	HOMA
O	1130	1135	index
O	1135	1136	<
O	1136	1137	2
O	1137	1138	.
O	1138	1139	8
O	1139	1140	)
O	1141	1142	,
O	1142	1147	there
O	1148	1151	was
O	1152	1153	a
O	1154	1160	higher
B-outcome	1161	1166	level
I-outcome	1167	1169	of
I-outcome	1170	1175	TUNEL
I-outcome	1176	1178	at
I-outcome	1179	1186	surgery
O	1187	1189	on
O	1190	1199	metformin
O	1200	1202	vs
O	1203	1210	placebo
O	1211	1212	(
O	1212	1218	median
O	1219	1229	difference
O	1230	1232	on
O	1233	1242	metformin
O	1243	1244	+
O	1244	1245	4
O	1245	1246	%
O	1246	1247	,
O	1248	1251	IQR
O	1251	1252	:
O	1253	1254	2
O	1254	1255	-
O	1255	1257	14
O	1258	1260	vs
O	1261	1262	+
O	1262	1263	2
O	1263	1264	%
O	1264	1265	,
O	1266	1269	IQR
O	1269	1270	:
O	1271	1272	0
O	1272	1273	-
O	1273	1274	7
O	1275	1277	on
O	1278	1285	placebo
O	1285	1286	)
O	1286	1287	,
O	1288	1295	whereas
O	1296	1298	an
O	1299	1307	opposite
O	1308	1313	trend
O	1314	1317	was
O	1318	1323	found
O	1324	1326	in
O	1327	1330	the
O	1331	1333	28
O	1334	1339	women
B-outcome	1340	1344	with
I-outcome	1345	1352	insulin
I-outcome	1353	1363	resistance
O	1364	1365	(
O	1365	1371	median
O	1372	1382	difference
O	1383	1385	on
O	1386	1395	metformin
O	1396	1397	+
O	1397	1398	2
O	1398	1399	%
O	1399	1400	,
O	1401	1404	IQR
O	1404	1405	:
O	1406	1407	0
O	1407	1408	-
O	1408	1409	6
O	1409	1410	,
O	1411	1413	vs
O	1414	1415	+
O	1415	1416	5
O	1416	1417	%
O	1417	1418	,
O	1419	1422	IQR
O	1422	1423	:
O	1424	1425	0
O	1425	1426	-
O	1426	1428	15
O	1429	1431	on
O	1432	1439	placebo
O	1439	1440	,
O	1441	1442	P
O	1442	1443	-
O	1443	1454	interaction
O	1454	1455	=
O	1455	1456	0
O	1456	1457	.
O	1457	1458	1
O	1458	1459	)
O	1459	1460	.

O	1461	1468	Overall
O	1468	1469	,
O	1470	1472	we
O	1473	1478	found
O	1479	1481	no
O	1482	1493	significant
B-outcome	1494	1504	modulation
I-outcome	1505	1507	of
I-outcome	1508	1517	apoptosis
O	1518	1520	by
O	1521	1530	metformin
O	1530	1531	,
O	1532	1540	although
O	1541	1546	there
O	1547	1550	was
O	1551	1552	a
O	1553	1558	trend
O	1559	1561	to
O	1562	1563	a
O	1564	1573	different
O	1574	1580	effect
O	1581	1590	according
O	1591	1593	to
O	1594	1601	insulin
O	1602	1612	resistance
O	1613	1619	status
O	1619	1620	,
O	1621	1625	with
O	1626	1627	a
O	1628	1635	pattern
O	1636	1646	resembling
O	1647	1651	Ki67
O	1652	1659	changes
O	1659	1660	.

O	1661	1670	Apoptosis
O	1671	1674	was
O	1675	1688	significantly
O	1689	1695	higher
O	1696	1698	in
O	1699	1702	the
O	1703	1711	surgical
O	1712	1721	specimens
O	1722	1730	compared
O	1731	1735	with
O	1736	1744	baseline
O	1745	1751	biopsy
O	1752	1755	and
O	1756	1759	was
O	1760	1768	directly
O	1769	1779	correlated
O	1780	1784	with
O	1785	1789	Ki67
O	1789	1790	.

O	1791	1794	Our
O	1795	1803	findings
O	1804	1811	provide
O	1812	1822	additional
O	1823	1831	evidence
O	1832	1835	for
O	1836	1837	a
O	1838	1842	dual
O	1843	1849	effect
O	1850	1852	of
O	1853	1862	metformin
O	1863	1865	on
O	1866	1868	BC
O	1869	1875	growth
O	1876	1885	according
O	1886	1888	to
O	1889	1896	insulin
O	1897	1907	resistance
O	1908	1914	status
O	1914	1915	.
